KR102559190B1 - 면역성 또는 염증성 질환 또는 암의 치료를 위해 유용한 7-(모르폴린-4-일)피라졸[1,5-a]피리미딘 유도체 - Google Patents

면역성 또는 염증성 질환 또는 암의 치료를 위해 유용한 7-(모르폴린-4-일)피라졸[1,5-a]피리미딘 유도체 Download PDF

Info

Publication number
KR102559190B1
KR102559190B1 KR1020177031214A KR20177031214A KR102559190B1 KR 102559190 B1 KR102559190 B1 KR 102559190B1 KR 1020177031214 A KR1020177031214 A KR 1020177031214A KR 20177031214 A KR20177031214 A KR 20177031214A KR 102559190 B1 KR102559190 B1 KR 102559190B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177031214A
Other languages
English (en)
Korean (ko)
Other versions
KR20170132275A (ko
Inventor
바바라 디멕
마르신 차고즈다
마치에 비에초렉
크르치슈토프 두비엘
알렉산드라 스탠착
다리아 츠드잘릭
파벨 구네르카
마리올라 세쿨라르
마치에 드치아첸
Original Assignee
셀론 파르마 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀론 파르마 에스.에이. filed Critical 셀론 파르마 에스.에이.
Publication of KR20170132275A publication Critical patent/KR20170132275A/ko
Application granted granted Critical
Publication of KR102559190B1 publication Critical patent/KR102559190B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177031214A 2015-04-02 2016-03-30 면역성 또는 염증성 질환 또는 암의 치료를 위해 유용한 7-(모르폴린-4-일)피라졸[1,5-a]피리미딘 유도체 Active KR102559190B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PL411864 2015-04-02
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Publications (2)

Publication Number Publication Date
KR20170132275A KR20170132275A (ko) 2017-12-01
KR102559190B1 true KR102559190B1 (ko) 2023-07-25

Family

ID=55650626

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031214A Active KR102559190B1 (ko) 2015-04-02 2016-03-30 면역성 또는 염증성 질환 또는 암의 치료를 위해 유용한 7-(모르폴린-4-일)피라졸[1,5-a]피리미딘 유도체

Country Status (18)

Country Link
US (1) US10138247B2 (https=)
EP (1) EP3277687B1 (https=)
JP (1) JP6665201B2 (https=)
KR (1) KR102559190B1 (https=)
CN (1) CN107743489B (https=)
AU (1) AU2016241568B2 (https=)
BR (1) BR112017020131B1 (https=)
CA (1) CA2978828A1 (https=)
DK (1) DK3277687T3 (https=)
EA (1) EA032826B1 (https=)
ES (1) ES2765642T3 (https=)
HR (1) HRP20192195T1 (https=)
HU (1) HUE047822T2 (https=)
MX (1) MX2017011423A (https=)
PL (2) PL236355B1 (https=)
PT (1) PT3277687T (https=)
SI (1) SI3277687T1 (https=)
WO (1) WO2016157091A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
WO2022064459A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
US20240018151A1 (en) * 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053716A1 (en) 2007-10-26 2009-04-30 F.Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
WO2010136491A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713673B2 (en) * 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
BRPI0607927A2 (pt) * 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
HRP20100516T1 (hr) * 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
MX2010009416A (es) 2008-02-26 2010-09-24 Novartis Ag Compuestos heterociclicos como inhibidores de cxcr2.
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
JP5578490B2 (ja) * 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
US8969364B2 (en) 2010-03-04 2015-03-03 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053716A1 (en) 2007-10-26 2009-04-30 F.Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
WO2010136491A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Also Published As

Publication number Publication date
BR112017020131A2 (pt) 2018-05-29
JP2018510192A (ja) 2018-04-12
ES2765642T3 (es) 2020-06-10
HUE047822T2 (hu) 2020-05-28
EP3277687B1 (en) 2019-10-30
CN107743489B (zh) 2021-05-04
EA032826B1 (ru) 2019-07-31
DK3277687T3 (da) 2019-12-16
PL411864A1 (pl) 2016-10-10
CN107743489A (zh) 2018-02-27
EP3277687A1 (en) 2018-02-07
EA201792087A1 (ru) 2018-03-30
JP6665201B2 (ja) 2020-03-13
MX2017011423A (es) 2018-05-17
SI3277687T1 (sl) 2020-02-28
PL236355B1 (pl) 2021-01-11
PL3277687T3 (pl) 2020-09-21
HRP20192195T1 (hr) 2020-03-06
PT3277687T (pt) 2020-01-10
US20180111939A1 (en) 2018-04-26
BR112017020131B1 (pt) 2023-02-28
KR20170132275A (ko) 2017-12-01
CA2978828A1 (en) 2016-10-06
US10138247B2 (en) 2018-11-27
AU2016241568B2 (en) 2019-09-26
AU2016241568A1 (en) 2017-10-19
WO2016157091A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
JP6298998B2 (ja) ウイルス感染を治療するための１，２，４−トリアジン誘導体
AU2022274298B2 (en) Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors
US10414769B2 (en) 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors
WO2014140582A1 (en) Kinase inhibitors
US20140121200A1 (en) Substituted pyridopyrazines as novel syk inhibitors
KR102559190B1 (ko) 면역성 또는 염증성 질환 또는 암의 치료를 위해 유용한 7-(모르폴린-4-일)피라졸[1,5-a]피리미딘 유도체
KR20230123922A (ko) 알파 단백질 키나제 1 억제제 및 사용 방법
WO2005085252A1 (en) Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
AU2023292912A1 (en) Prodrugs of stat3 inhibitors
CN117043144A (zh) 作为lpa受体2抑制剂的8-环-取代的喹唑啉衍生物
KR102539761B1 (ko) 2-티옥소티아졸리딘-4-온 유도체 화합물 및 이의 용도
ES2845230T3 (es) Derivados de pirazol[1,5-a]pirimidina como inhibidores de quinasa JAK
WO2025143152A1 (ja) チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用
US20240116947A1 (en) Pyrido oxazine derivatives as alk5 inhibitors
BR112019023480B1 (pt) DERIVADOS DE PIRAZOLO [1,5 -a] PIRIMIDINA COMO INIBIDORES DE QUINASE JACK
CA3013404A1 (en) Morpholinopyridine derivatives and compositions thereof for use as kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171027

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210326

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230404

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230623

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230720

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230721

End annual number: 3

Start annual number: 1

PG1601 Publication of registration